NOVARTIS - KESIMPTA NOVARTIS PRESENTED STRONG EXTENSION STUDY DATA OF KESIMPTA AT THE EAN 2022 CONGRESS Novartis announced new data from...

Bristol Myers Squibb announced that Breyanzi (lisocabtagene maraleucel) was approved by the U.S. Food and Drug Administration (FDA) for...